<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69291">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02203773</url>
  </required_header>
  <id_info>
    <org_study_id>M14-358</org_study_id>
    <secondary_id>2014-000687-18</secondary_id>
    <nct_id>NCT02203773</nct_id>
  </id_info>
  <brief_title>Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)</brief_title>
  <official_title>A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety of
      orally administered ABT-199 combined with decitabine or azacitidine and the preliminary
      efficacy of these combinations. In addition, there is a DDI sub-study only at a single site,
      to assess the pharmacokinetics and safety of ABT-199 in combination with posaconazole.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine</measure>
    <time_frame>Measured from Day 1 up to 2 years after the last subject has enrolled</time_frame>
    <description>AE monitoring will be assessed by evaluation of study drug exposure, AEs , serious AEs, all deaths, as well as laboratory determinations and vital sign parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>Maximum observed concentration, occurring at Tmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The time to Cmax (peak time, Tmax),</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>The time at which maximum plasma concentration (Cmax) is observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt)</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from 0-24 (AUC0-24)</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) over a 24-hour dose interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>half-life (t1/2)</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>The time required for the concentration of the drug to reach half of its original value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from 0 to infinity (AUC∞)</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>Area under the plasma concentration-versus-time curve from time zero to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>Clearance is defined as the rate at which drug is cleared from the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Remission Rate</measure>
    <time_frame>Measured up to 2 years after the last subject enrolled has their last study visit.</time_frame>
    <description>Complete Remission Rate will be determined by the number of subjects who achieve a Complete Remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Remission with incomplete blood count recovery rate</measure>
    <time_frame>Measured up to 2 years after the last subject has their last study visit.</time_frame>
    <description>Complete Remission with incomplete blood count recovery Rate will be determined by the number of subjects who achieve a Complete Remission with incomplete blood count recovery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Measured up to 2 years after the last subject enrolled has their last study visit.</time_frame>
    <description>Overall response rate will be defined as the proportion of subjects who achieve a complete remission (CR), complete remission incomplete (CRi), or partial remission(PR) per the International Working Group criteria for AML.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Measured up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>Duration of response will be defined as the number of days from the date of first response per the IWG criteria for AML to the earliest recurrence or progressive disease (PD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Measured up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>Overall survival will be defined as the number of days from the date of enrollment to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD) Negativity Rate</measure>
    <time_frame>Measured up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>The presence of less than one AML cell per 10,000 leukocytes in either peripheral blood and/or bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in clinical laboratory test results</measure>
    <time_frame>Measured from Day 1 up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>chemistry, hematology, and urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in physical exam findings, including vital signs.</measure>
    <time_frame>Measured from Day 1 up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>Body temperature, weight, blood pressure, heart rate, and respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects who move on to stem cell transplant</measure>
    <time_frame>Measure up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>The percent of subjects who move on to stem cell transplant will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>Measured up to 2 years after the last subject enrolled has their last study visit.</time_frame>
    <description>Event-free survival (EFS) will be defined as the number of days from the date of first dose to the date of earliest evidence of relapse, subsequent treatment other than stem cell transplant while in composite complete response (CR + CRi), or death.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelogenous Leukemia</condition>
  <condition>Treatment Naive AML</condition>
  <arm_group>
    <arm_group_label>ABT-199 + Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Naive Acute Myelogenous Leukemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-199 + Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Naive Acute Myelogenous Leukemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-199+Decitibine+Posaconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Naive Acute Myelogenous Leukemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-199</intervention_name>
    <description>ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.</description>
    <arm_group_label>ABT-199 + Decitabine</arm_group_label>
    <arm_group_label>ABT-199 + Azacitidine</arm_group_label>
    <arm_group_label>ABT-199+Decitibine+Posaconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles</description>
    <arm_group_label>ABT-199 + Decitabine</arm_group_label>
    <arm_group_label>ABT-199+Decitibine+Posaconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.</description>
    <arm_group_label>ABT-199 + Azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole</intervention_name>
    <description>Posaconazole will be administered twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.</description>
    <arm_group_label>ABT-199+Decitibine+Posaconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have confirmation of AML by WHO criteria25 and be ineligible for
             treatment with a standard cytarabine and anthracycline induction regimen due to
             co-morbidity or other factors.

          2. Subject must have received no prior treatment for AML with the exception of
             hydroxyurea.

          3. Subject must be ≥ 60 years of age.

          4. Subject must have a projected life expectancy of at least 12 weeks.

          5. Subject must be considered ineligible for induction therapy defined by the following:

               -  ≥ 75 years of age; OR

               -  ≥ 60 to 74 years with at least one of the following co-morbidities:

                    -  ECOG Performance Status of 2 or 3;

                    -  Cardiac history of CHF requiring treatment or Ejection Fraction ≤ 50% or
                       chronic stable angina;

                    -  DLCO ≤ 65% or FEV1 ≤ 65%;

                    -  Creatinine clearance ≥ 30 mL/min to &lt; 45 ml/min Moderate hepatic impairment
                       with total bilirubin &gt;1.5 to ≤ 3.0 × ULN

                    -  Any other comorbidity that the physician judges to be incompatible with
                       intensive chemotherapy must be reviewed and approved by the study medical
                       monitor before study enrollment

          6. Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status:

               -  0 to 2 for subjects ≥ 75 years of age OR

               -  0 to 3 for subjects ≥ 60 to 74 years of age.

          7. Subject must have adequate renal function as demonstrated by a calculated creatinine
             clearance ≥ 30 mL/min; determined via urine collection for 24-hour creatinine
             clearance or by the Cockcroft Gault formula.

          8. Subject must have adequate liver function as demonstrated by:

               -  aspartate aminotransferase (AST) ≤ 3.0 × ULN*

               -  alanine aminotransferase (ALT) ≤ 3.0 × ULN*

               -  bilirubin ≤ 1.5 × ULN* ○ Subjects &gt; 60 to 74 years of age may have bilirubin ≤
                  3.0 × ULN* * unless considered due to leukemic organ involvement.

          9. Non-sterile male subjects must use contraceptive methods with partner(s) prior to
             beginning study drug administration and continuing up to 90 days after the last dose
             of study drug. Male subjects must agree to refrain from sperm donation from initial
             study drug administration until 90 days after the last dose of study drug.

         10. Female subjects must be either:

               -  Postmenopausal; defined as Age &gt; 55 years with no menses for 12 or more months
                  without an alternative medical cause; OR

               -  Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or
                  hysterectomy).

        Exclusion Criteria:

          1. Subject has received treatment with the following:

               -  hypomethylating agent and/or chemo therapeutic agent for Myelodysplastic
                  syndrome [MDS])

               -  CAR-T cell therapy

               -  Other experimental therapies for AML.

          2. Subject has history of Myloproliferative Neoplasm (MPN).

          3. Subject has favorable risk cytogenetics as categorized by the NCCN Guidelines Version
             2, 2016 for Acute Myeloid Leukemia (Appendix D).

          4. Subject has t(8;21), inv(16), t(16;16) or t(15;17) karyotype abnormalities.

          5. Subject has acute promyelocytic leukemia.

          6. Subject has known active CNS involvement from AML.

          7. Subject is known to be positive for HIV. Note: HIV testing is not required.

          8. Subject is known to be positive for hepatitis B or C infection with the exception of
             those with an undetectable viral load. Note: Hepatitis B or C testing is not required
             and subjects with serologic evidence of prior vaccination to HBV (i.e., HBs Ag-,
             anti-HBs+ and anti-HBc-) may participate.

          9. Subject has received a strong and/or moderate CYP3A inducer within 7 days prior to
             the initiation of study treatment.

         10. Subject has consumed grapefruit, grapefruit products, Seville oranges (including
             marmalade containing Seville oranges) or Star fruit within 3 days prior to the
             initiation of study treatment.

         11. Subject has any history of clinically significant condition(s) that in the opinion of
             the investigator would adversely affect his/her participating in this study
             including, but not limited to:

               -  cardiovascular disability status of New York Heart Association Class ≥ 2. Class
                  2 is defined as cardiac disease in which patients are comfortable at rest but
                  ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal
                  pain.

               -  renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic,
                  cardiovascular disease, or bleeding disorder independent of leukemia,

               -  chronic respiratory disease that requires continuous oxygen use.

         12. Subject has a malabsorption syndrome or other condition that precludes enteral route
             of administration.

         13. Subject exhibits evidence of uncontrolled systemic infection requiring therapy
             (viral, bacterial or fungal).

         14. Subject has a history of other malignancies prior to study entry, with the exception
             of:

               -  Adequately treated in situ carcinoma of the breast or cervix uteri;

               -  Basal cell carcinoma of the skin or localized squamous cell carcinoma of the
                  skin;

               -  Previous malignancy confined and surgically resected (or treated with other
                  modalities) with curative intent.

         15. Subject has a white blood cell count &gt; 25 × 109/L. Note: Hydroxyurea is permitted to
             meet this criterion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jalaja Potluri, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847-283-8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129718</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129718, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129719</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129719, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127859</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127859, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129715</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129715, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128741</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 128741, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128742</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 128742, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129699</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129699, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127857</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127857, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130289</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 130289, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129720</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129720, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127860</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 127860, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141581</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141581, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129717</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129717, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130352</name>
      <address>
        <city>East Melbourne</city>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 130352, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130356</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 130356, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130353</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 130353, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134388</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 134388, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134389</name>
      <address>
        <city>Toulouse, Cedex 09</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 134389, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130342</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 130342, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130346</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 130346, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130347</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 130347, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130341</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 130341, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 17, 2017</lastchanged_date>
  <firstreceived_date>July 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Treatment Naive AML</keyword>
  <keyword>ABT-199</keyword>
  <keyword>GDC-0199</keyword>
  <keyword>Untreated AML</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Myelogenous Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
